Ankylosing Spondylitis (AS), Axial Spondyloarthritis (axSpA)
Conditions
Brief summary
the main objectives are 1. to study the pathophysiological role of KIR3DL2 in axSpA and its relationship with Th17 immunity in HLA-B27 + and HLA-B27- patients and 2. to assess the effect on the pro-inflammatory immune response of a cytotoxic monoclonal antibody IPH4102 (anti-KIR3DL2) in these patients. The study will be carried out on blood samples from 24 patients with axSpA, 12 HLA-B27 + and 12 HLA-B27-, without any drug injection nor direct therapeutic benefit for the participating patients and 12 healthy controls.
Interventions
BIOLOGICALblood samples
7 tubes of 6 ml (42 ml of blood )
Sponsors
Assistance Publique Hopitaux De Marseille
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Informed consent of the patient signed before any procedure planned to the protocol * SPA axial according to the criteria of the ASAS (international Assessment of SpondyloArthritis Society) * Known Status HLA B27 * Disease activates with a score of BASDAI = 4/10. The BASDAI (Bath Ankylosing Spondylitis Disease Activity Score) is a composite indication(index), validated, used in the therapeutic essays and in current practice for the evaluation of the activity of the SPA. * Naive Patients of thorough treatment * Patients of 18 and more years old
Exclusion criteria
* Minors * Pregnant or breast-feeding Women * Adults under guardianship * People staying in a sanitary or social establishment * People in emergency situation * Not profitable People of a national insurance scheme * Private persons of freedom * Treatment by corticoids during the last 30 days before the inclusion * Treatment by anti-TNF or quite different biomedicine * Treatment by sulfasalazine * Reached concomitant by another active chronic inflammatory disease * Infection chronicles by VHB, VHC or HIV * Patients included in another study of clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characterize the present various immunizing populations in patients' blood SPA HLA-B27 + and HLA-B27-(Lymphocytes T CD4 (Th1 Th2, Th17, Tregs), lymphocytes T CD8, cells NK, lymphocytes B, monocytes) | 12 MONTHS | by flow cytometry. |
Secondary
| Measure | Time frame |
|---|---|
| Expression of the receivers involved in SPA on lymphocytes T CD4 in percentage of cells T CD4 expressing this markers | 12 MONTHS |
| Dosage of cytokines | 12 MONTHS |
Countries
France
Contacts
STUDY_DIRECTORjean olivier ARNAUD
Assistance Publique Hopitaux De Marseille
Outcome results
None listed